Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Operating Costs and Expenses:
General and administrative	$ 8,074	$ 6,013	$ 5,832
Research and development	32,906	14,489	6,507
Total Operating Costs and Expenses	40,980	20,502	12,339
Loss from Operations	(40,980)	(20,502)	(12,339)
Other Income (Expense):
Change in fair value of warrant liability	(3,811)	620	0
Other income (expense)	0	95	(12)
Interest income	6	3	33
Total Other Income (Expense)	(3,805)	718	21
Net Loss	(44,785)	(19,784)	(12,318)
Net Loss Attributable to Non-controlling Interest	(1,048)	0	(1)
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries	$ (43,737)	$ (19,784)	$ (12,317)
Net Loss Per Share - Basic and Dilutive (in dollars per share)	$ (0.54)	$ (0.32)	$ (0.27)
Net Income (Loss) Per Share - Basic and Dilutive
Weighted average number of shares outstanding during the period - Basic and Dilutive (in shares)	80,705,692	61,945,356	45,667,813